Reproducing human and cross-species drug toxicities using a Liver-Chip
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Nonclinical rodent and nonrodent toxicity models used to support clinical trials of candidate drugs may produce discordant results or fail to predict complications in humans, contributing to drug failures in the clinic. Here, we applied microengineered Organs-on-Chips technology to design a rat, dog, and human Liver-Chip containing species-specific primary hepatocytes interfaced with liver sinusoidal endothelial cells, with or without Kupffer cells and hepatic stellate cells, cultured under physiological fluid flow. The Liver-Chip detected diverse phenotypes of liver toxicity, including hepatocellular injury, steatosis, cholestasis, and fibrosis, and species-specific toxicities when treated with tool compounds. A multispecies Liver-Chip may provide a useful platform for prediction of liver toxicity and inform human relevance of liver toxicities detected in animal studies to better determine safety and human risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the current available in vivo and in vitro DILI models have low and inadequate predictive capability.7,8”
From A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids (2024) · cites this paper as [8]
In the citing paper
“Albumin and urea production are widely accepted as functional markers for cultured hepatocytes with the goal of reaching computed production levels observed in human liver in vivo (~20–105 µg and 56–159 µg per 106 hepatocytes per day, respectively)19,26.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [26]
In the citing paper
“as well as superior activity relative to hepatocytes in a 2D sandwich-assay plate configuration26.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [26]
In the citing paper
“previously, the same Liver-Chip has been shown to exhibit Phase I and II functional activities that are comparable to freshly isolated human hepatocytes and 3D hepatic spheroids26,30”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [26]
Citations
Cites
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Self-citationBhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Self-citationConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“An analysis of 150 drugs that caused adverse events in humans found that regulatory testing in rats and dogs correctly predicted just 71% of toxicities in humans (1).”
BackgroundFrom 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834 · cited 1×
“In addition, dense 3D constructs often suffer from limited oxygen and nutrient transport, and even when spheroid cultures include endothelial cells and Kupffer cells, they lack physiologically relevant tissue-tissue interfaces and cytoarchitecture that has been demonstrated to be a key driver of cell function (10, 42).”
BackgroundSelf-citationOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Mechanisms of Acetaminophen-Induced Liver Necrosis
Hinson, J. A., Roberts, D. W., & James, L. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00663-0_12 · Cited by 1,006 · cited 1×
“APAP toxicity is caused by direct injury to hepatocytes mediated by the toxic and reactive metabolite N-acetyl-p-benzoquinone imine that depletes cellular glutathione (GSH), causing oxidative stress; it can also be detoxified by hepatocytes, resulting in formation of glucuronide and sulfate metabolites (27).”
BackgroundBjörnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment
Jang, K.-J., Mehr, A. P., Hamilton, G. A., McPartlin, L. A., Chung, S., Suh, K.-Y., & Ingber, D. E. (2013) · Integrative Biology · doi:10.1039/c3ib40049b · Cited by 849
Self-citationMcGill, M. R., Sharpe, M. R., Williams, C. D., Taha, M., Curry, S. C., & Jaeschke, H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59755 · Cited by 763 · cited 1×
“Mitochondrial dysfunction has been identified as a hazard for APAP toxicity (47).”
BackgroundDevelopment of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids
Kasendra, M., Tovaglieri, A., Sontheimer-Phelps, A., Jalili-Firoozinezhad, S., Bein, A., Chalkiadaki, A., Scholl, W., Zhang, C., Rickner, H., Richmond, C. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21201-7 · Cited by 754
Self-citation
Research works printed but not linked: 3
- Food and Drug Administration Drug Approval Package : Tracleer (Bosentan) (Food and Drug Administration 2001) pp. 21–290.
- Institute of Medicine (U.S) Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials in Review of the Fialuridine (FIAU) Clinical Trials F. J. Manning M. N. Swartz Eds. (National Academy Press 1995) 269 pp.
- Food and Drug Administration The Food and Drug Administration Predictive Toxicology Roadmap and Its Implementation; Public Hearing; Request for Comments (Office of the Federal Register National Archives and Records Administration 2018) vol. 83 pp. 30595–30598.
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
Self-citationA guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
Organ-on-a-Chip: A New Paradigm for Drug Development
Ma, C., Peng, Y., Li, H., & Chen, W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.009 · Cited by 576
“Many drugs may show no adverse effects on animals during the preclinical stage but unpredictably exhibit hepatic, cardiac, or renal impairments in patients during clinical trials [3, 4].”
Background
Metadata
- Authors
- Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., Nawroth, J., Simic, D., Lam, W., Singer, M., Barale, E., Singh, B., Sonee, M., Streeter, A. J., Manthey, C., Jones, B., Srivastava, A., Andersson, L. C., Williams, D., Park, H., Barrile, R., Sliz, J., Herland, A., Haney, S., Karalis, K., Ingber, D. E., & Hamilton, G. A.
- Affiliations
- Emulate (United States) (US)
- Janssen Pharmaceutical Research and Development, Nonclinical Safety, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
- Janssen Pharmaceutical Research and Development, Drug Metabolism and Pharmacokinetics, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
- AstraZeneca (United Kingdom) (GB)
- Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
- Janssen Pharmaceutical Research and Development, IPD Biology, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
- AstraZeneca (Sweden) (SE)
- Harvard University (US)
- Boston Children's Hospital (US)
- Corresponding author
- Otieno, Monicah A.
- Hamilton, Geraldine A.
- ORCID
- Jang, Kyung-Jin
- Otieno, Monicah A.
- Ronxhi, Janey
- Lim, Heng-Keang
- Ewart, Lorna
- Kodella, Konstantia R.
- Petropolis, Debora B.
- Kulkarni, Gauri
- Rubins, Jonathan E.
- Conegliano, David
- Nawroth, Janna
- Lam, Wing
- Singer, Monica
- Barale, Erio
- Singh, Bhanu
- Sonee, Manisha
- Streeter, Anthony J.
- Manthey, Carl
- Srivastava, Abhishek
- Andersson, Linda C.
- Williams, Dominic
- Park, Hyoungshin
- Barrile, Riccardo
- Sliz, Josiah
- Herland, Anna
- Karalis, Katia
- Ingber, Donald E.
- Hamilton, Geraldine A.
- Venue
- Science Translational Medicine
- Published
- 2019-11-06
- Volume
- 11
- Issue
- 517
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2983383732
- Cited by
- 511
- References
- 52
- Citations by year
- 2026: 87 · 2025: 73 · 2024: 66 · 2023: 71 · 2022: 79 · 2021: 83 · 2020: 47 · 2019: 5
- FWCI
- 53.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Janssen Biotech
- Janssen Pharmaceuticals
- the Defense Advanced Research Projects Agency (W911NF-12-2-0036)
- the Wyss Institute for Biologically Inspired Engineering at Harvard University
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- organ-on-a-chip, drug toxicity prediction, hepatotoxicity, species-specific toxicity, primary hepatocytes, liver sinusoidal endothelial cells, Kupffer cells, hepatic stellate cells, hepatocyte injury, steatosis, cholestasis, liver fibrosis, microfluidic organ models
- MeSH terms
- Animals, Dogs, Humans, Kupffer Cells, Liver, Liver Diseases, Phenotype, Risk Factors, Species Specificity, Reproducibility of Results, Biomarkers, Rats, Chemical and Drug Induced Liver Injury, Lab-On-A-Chip Devices, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reproducing human and cross-species drug toxicities using a Liver-Chip. https://app.cochat.ai/papers/10.1126/scitranslmed.aax5516
- The paper
- Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., Nawroth, J., Simic, D., Lam, W., Singer, M., Barale, E., Singh, B., Sonee, M., Streeter, A. J., Manthey, C., . . . Hamilton, G. A. (2019). Reproducing human and cross-species drug toxicities using a Liver-Chip. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aax5516
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.